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Anaesthesia for the preeclamptics patient?
Abstract
Preeclampsia is a multisystem disorder of unknown exact origin in preg-
nancy. Three mayor signs of preeclamsia are: hypertension, oedema and pro-
teinuria. Treatement is symptomatic,delivery contributes to cessation of
symptomes, but not immidiately.
Anesthesia and analgesia for labour can be epidural, spinal or combined
epidural-spinal there are safe according to new dana in literaure, but always
paying attention to coagulation status. The major problem is to control
hypertension but also to avoide hypotensive episodes that contribute to
mothers and childs morbidity and mortality.
INTRODUCTION
Preeclampsia is a multisystem disorder in pregnancy. Preeclampsiacomplicates up to 8% of pregnancies in the world. Preeclampsia is a
major cause of maternal mortality and morbidity, preterm birth and
perinatal death (1). 10%–15% of maternal deaths are directly associated
with pre-eclampsia and eclampsia (2). The incidence of pre-eclampsia
ranges from 3% to 7% in healthy nulliparas and 1% to 3% in multiparas
(3).
Carefull control of the blood pressure in the parturients is necesery
because high pressure is one of the first warning signals. The obstetric
anaesthetist has to prevent the effects of developed organ dysfunction of
the cardiorespiratory, cerebral and coagulation systems that is present
in preeclampsia and eclampsia (4).
Preeclampsia is a complex multi-system disorder that may sometimes
proceade to eclampsia. Preeclampsia is associated with widespread endo-
thelial dysfunction leading to placental ischaemia and multi-organ
dysfunction in parturient (5).
Controversies still exist with regard to its aetiology, diagnosis and
treatment.
The exact aetiology of preeclampsia is unknown and probably com-
plex. It only occurs in the presence of placental tissue and may be de-
pendent on immunological and genetic factors (6).
Preeclampsia has a complex pathophysiology, the primary cause
being abnormal placentation. The abnormalities may be related to the
nitric oxide pathway, which contributes substantially to the control of
vascular tone. Inhibition of maternal synthesis of nitric oxide prevents
embryo implantation (7).
Increased uterine arterial resistance induces higher sensitivity to
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Clinical experience
stress. This chronic placental ischemia causes fetal com-
plications, including intrauterine growth retardation and
intrauterine death (7).
Oxidative stress induces release into the maternal cir-
culation substances such as free radicals, oxidized lipids,
cytokines, and serum soluble vascular endothelial growth
factor 1. These abnormalities are responsible for endo-
thelial dysfunction with vascular hyperpermeability,
thrombophilia, and hypertension. That compensate the
decreased flow in the uterine arteries due to peripheral
vasoconstriction (7, 8).
During normal pregnancy placental produces equal
amounts of prostacyclin and thromboxane, but in pre-
eclamptic pregnancy produces seven times more throm-
boxane than prostacyclin. This is as resultat of reduced
placental perfusion and release of substances causing
endothelial cell injury (8).
Diagnostic triad for preeclampsia is: hypertension,
proteinuria and oedema. Oedema occurs in up to 80% of
normotensive parturients.
Hypertension is usually developing after 20 weeks of
pregnancy. Hypertension in pregnancy is defined as a
systolic pressure of over 140 mmHg and /or a diastolic
pressure less then 90 mmHg (4).
Patients with preeclampsia are at risk of developing
pulmonary oedema due to low colloid oncotic pressure
and increased vascular permeability (4).
Coagulation changes in preeclampsia. Early in the di-
sease the hyper-coagulable state of normal pregnancy may
be enhanced. Later, both platelet activation and consump-
tion are increased which can lead to significant thrombo-
cytopenia (platelet count <100,000 mm-3) in approxi-
mately 15% of women with severe preeclampsia (1).
Disseminated intravascular caogulation (DIC) occurs
in 7% of cases of severe preeclampsia.
The proteinuria of severe preeclampsia occurs later
and reflects as ischaemic insult to the glomerulus. Patients
develop oliguria, in severe preeclampsia proteinuria may
exceed 500mg/day (2, 3).
Abnormal liver function tests are frequently found in
preeclampsia.
The neurological changes with severe preeclampsia
include headaches, visual disturbances and hyperreflexia.
Cerebral vasospasm has been demonstrated by intra-
cranial Doppler in patients with preeclampsia and MRI
studies demonstrated reduced blood flow. Ischaemia due
to vasospasm and/or cerebral oedema may be the cause of
neurological symptoms (2, 3, 4).
THERAPY FOR PREECLAMTIC PATIENTS
Drug therapy in preeclampsia is based on symptoma-
tic organ support and prevention of complications.
Termination of delivery remains the only curative
treatment for preeclampsia although the disease process
may not resolve immediately.
Anti hypertensive treatment is necesary to prevent
maternal and fetal morbidity.
Magnesium Sulphate (MgSO4) is the anticonvulsant
of choice in preventing and treating eclamptic fits. It is
usually administered as a slow intravenous bolus of 4 to 6
grams and then as an infusion of 1- 2 grams per hour to
keep the serum Mg in the therapeutic range. MgSO4 is a
safe drug to use in the pregnant patient but the most
important effect of moderately high levels is the effect on
the neuromuscular junction. MgSO4 may also increase
the episodes of hypotension during regional anaesthesia
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TABLE 1
Anti-hypertensive drugs
and will tend to blunt the response to vasoconstrictors.
Treatment of overdose is supportive in the first instance
and also includes intravenous calcium (e.g. Calcium glu-
conate 1g). Magnesium therapy is often continued for at
least 24 hours post partum (9).
Administration of fluid may be necessary to avoid the
prerenal oliguria that is common with preeclamptic pa-
tients. Furosemide may be used to treat persistent oligu-
ria in the presence of an adequately filled circulation.
The presence of hypoalbuminaemia, increased capil-
lary permeability and a high hydrostatic pressure (from
the hypertension) leads to the risk of pulmonary and
pharyngolaryngeal oedema.
Thrombocytopenia is a common problem in severe
preeclampsia but there is no absolute level of platelet
count that accurately predicts the occurrence of bleeding
associated with regional anaesthesia.
REGIONALNA ANESTHESIA FOR
PREECLAMTIC PARTURIENS
Epidural anesthesia has been accepted as the pre-
ferred anesthetic technique for cesarean delivery in seve-
rely preeclamptic patients. Epidural analgesia may safely
be extended for caesarean section. The block should be
developed slowly with a weak solution of local anaes-
thetic and opiate and the blood pressure measured fre-
quently for at least the first 20 minutes. Epidural anal-
gesia is an ideal form of pain relief during labour in a
preeclamptic patient. It helps to control the exaggerated
hypertensive response to pain and can also improve the
placental blood flow in these patients (10).
A spinal analgesia is quicker and involves less poten-
tial trauma in the epidural space. Spinal anesthesia can
be performed faster, has fewer complications, and is more
cost-effective for uncomplicated cesarean delivery.
Spinal anesthesia for cesarean delivery in severely
preeclamptic patients causes slightly more hypotension
than does epidural anesthesia during the induction to
delivery period. The duration of hypotension, however,
was short and there was no difference in neonatal status
(10).
In a morbidly obese preeclamptic parturients a single
dose of 9-15 mg of hyperbaric bupivacaine is considered
as safe and effective dose for spinal anesthesia (11).
The addition of an opioid with a lower local anes-
thetic dose may decrease hypotension. Ben-David et al.
investigated the use of opioid in low dose spinal anes-
thesia and concluded that a lower local anesthetic dose
combined with opioid provided adequate anesthesia and
decreased the incidence of hypotension by 30% (12).
Morbidly obese preeclamptic parturient often have
comorbid disease states such as hypertension and dia-
betes. Other physiologic changes associated with obesity
include increased oxygen demand and CO2 production,
decreased lung compliance, increased cardiac work load
and gastric reflux (13).
Hogan et al. studied the influence of body habitus on
cerebrospinal fluid volume with magnetic resonance imag-
ing studies. They concluded that patients with increased
abdominal compression, as seen in obese and gravid
patients, have lower cerebrospinal fluid volumes. Car-
penter et al. showed that at a fixed dose of local anes-
thetic, there was an inverse correlation between cere-
brospinal fluid volume and height sensory block. In the
morbidly obese gravid patient, cerebrospinal fluid volu-
me may perhaps be a contributing factor affecting dose
requirement (14).
M Reyes and P.H Pan described in a severe morbidly
preeclamptic parturient that very low total dose of 5 mg
hyperbaric bupivacaine was sufficient for cesarean sec-
tion without the need of any supplements.
In the spinal and epidural anesthesia groups ephe-
drine use was similar, in the Hood and Curry study (23
and 26%) and Wallace et al. study (22 and 30%), res-
pectively. In Visalyaputra et al. study ephedrine was ad-
ministered more often in the spinal group (72%) than in
the epidural group (45%).
Although the incidence of hypotension and ephedrine
requirement was slightly more frequent in the spinal
group than in the epidural group, we found evidence that
supports the use of spinal anesthesia in severely preeclam-
ptic patients (16, 17).
Difference in mean lowest MAP (mean difference,
10 mm Hg) did not appear to be clinically significant.
The hypotension was easily treated and there was
only a brief period of significant hypotension in either
group.
The neonatal outcomes assessed by the Apgar score
and the umbilical arterial blood gas analysis were similar
in both groups.
Newborns who were born with the maximum dura-
tion times of hypotension in both groups had 5-min
Apgar scores and umbilical arterial blood pH within nor-
mal ranges.
A combined spinal- epidural approach can be used
with a limited dose of local anaesthetic in the subarach-
noid space and the option of utilising the epidural space
as necessary (18).
SUMMARY
Although the incidence of hypotension and ephedrine
requirement was slightly more frequent in the spinal
group than in the epidural group, we found evidence that
supports the use of spinal anesthesia in severely pre-
eclamptic patients. The difference in mean lowest MAP
(mean difference, 10 mm Hg) did not appear to be clini-
cally significant. The hypotension was easily treated and
there was only a brief period of significant hypotension in
either group. The neonatal outcomes assessed by the
Apgar score and the umbilical arterial blood gas analysis
were similar in both groups.
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